| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
CYP3A4 is the primary enzyme responsible for the formation of 4beta-hydroxycholesterol from cholesterol. This compound is used as an analytical standard; it does not directly interact with biological targets itself.
|
|---|---|
| ln Vitro |
Drug compounds have been modified to include stable heavy isotopes of hydrogen, carbon, and other elements. These isotopes are mostly utilized as quantitative tracers during the drug development process. 1].
Not applicable; as a stable isotope-labeled internal standard, it is not tested for biological activity in vitro. Its non-labeled counterpart, 4beta-hydroxycholesterol, is a circulating metabolite that reflects CYP3A4 activity. |
| ln Vivo |
Not applicable; this compound is an analytical standard not intended for in vivo administration. The non-labeled version is an endogenous metabolite present in human circulation (typical concentrations 20-100 ng/mL).
|
| Enzyme Assay |
4beta-Hydroxycholesterol-d4 is spiked into biological samples (plasma, serum, or liver microsomes) at known concentrations (e.g., 10-50 ng/mL) prior to extraction. Samples are processed by liquid-liquid extraction and analyzed by LC-MS/MS (MRM transitions monitored).
|
| Cell Assay |
Not applicable; no cell-based assays are performed with this internal standard. It is used in analytical chemistry workflows involving mass spectrometry quantification of biological specimens.
|
| Animal Protocol |
Not applicable; this compound is not administered to animals. It is used to quantify endogenous 4beta-hydroxycholesterol levels in animal study samples (e.g., plasma from rats or mice treated with CYP3A inducers/inhibitors).
|
| ADME/Pharmacokinetics |
Not applicable; this is an analytical internal standard. The endogenous 4beta-hydroxycholesterol in humans has a plasma half-life of approximately 17 days, making it a useful long-term marker of CYP3A4 activity.
|
| Toxicity/Toxicokinetics |
No toxicity; the compound is used as an analytical standard at picogram to nanogram levels in LC-MS/MS. It does not pose a toxicological risk in research applications.
|
| References |
|
| Additional Infomation |
4beta-Hydroxycholesterol-d4 is for research use only, not clinically approved. It is a valuable tool for CYP3A4 phenotyping, drug-drug interaction studies, and biomarker validation.
|
| Molecular Formula |
C27H42D4O2
|
|---|---|
| Molecular Weight |
406.67800
|
| Exact Mass |
406.375
|
| CAS # |
1363529-44-5
|
| PubChem CID |
57332228
|
| Appearance |
White to off-white solid powder
|
| LogP |
6.359
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
29
|
| Complexity |
624
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
[2H]C([2H])([2H])C([2H])(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H]([C@@H]4O)O)C)C
|
| InChi Key |
CZDKQKOAHAICSF-LIDHSRKFSA-N
|
| InChi Code |
InChI=1S/C27H46O2/c1-17(2)7-6-8-18(3)20-11-12-21-19-9-10-23-25(29)24(28)14-16-27(23,5)22(19)13-15-26(20,21)4/h10,17-22,24-25,28-29H,6-9,11-16H2,1-5H3/t18-,19+,20-,21+,22+,24+,25-,26-,27-/m1/s1/i1D3,17D/t17?,18-,19+,20-,21+,22+,24+,25-,26-,27-
|
| Chemical Name |
(3S,4R,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6,7,7,7-tetradeuterio-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,4-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4589 mL | 12.2947 mL | 24.5894 mL | |
| 5 mM | 0.4918 mL | 2.4589 mL | 4.9179 mL | |
| 10 mM | 0.2459 mL | 1.2295 mL | 2.4589 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
